Details of Disease

General Information of Disease (ID: DIS02PWG)

• Disease Name: Rosacea
• Synonyms: acne, erythematosa; acne roscea; acne rosacea
• Disease Class: ED90: Rosacea
• Definition: A chronic erythematous skin disorder that affects the face. It is characterized by the development of redness in the cheeks, nose, and/or forehead and telangiectasia. Sometimes, the erythematous changes may involve the eyelids.
• Disease Hierarchy:
  DIS9YPUQ: Dermatological disease
  DIS02PWG: Rosacea
• ICD Code:
  ICD-11: ICD-11: ED90.0
  ICD-10: ICD-10: L71.8, L71.9
  Expand ICD-11: 'ED90.0
  Expand ICD-10: 'L71.8; 'L71.9
• Disease Identifiers:
  MONDO ID: MONDO_0006604
  MESH ID: D012393
  UMLS CUI: C0035854
  MedGen ID: 11269
  SNOMED CT ID: 398909004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Clobetasol	DMUXP52	Approved	Small molecular drug	[1]
Clocortolone	DM9ZMQH	Approved	Small molecular drug	[1]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[2]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[3]
Diflorasone	DMI9PRJ	Approved	Small molecular drug	[1]
Dromostanolone	DMF2JDG	Approved	Small molecular drug	[4]
Fluorometholone	DM2HKC4	Approved	Small molecular drug	[5]
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[6]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[7]
Medrysone	DMJ90O5	Approved	Small molecular drug	[8]
Minocycline	DMVN5OH	Approved	Small molecular drug	[9]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[10]
Tobramycin	DMUI0CH	Approved	Small molecular drug	[11]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FMX103	DM46PFX	Phase 3	NA	[9]
Omiganan	DM7UF9M	Phase 3	NA	[9]
VERED	DMY7R7E	Phase 3	NA	[9]
AOB103	DMLO02P	Phase 2	NA	[9]
BPX-04	DM7JIBP	Phase 2	NA	[9]
DER-45-EV	DMKVI7E	Phase 2	NA	[12]
DFD-04	DMBRVMH	Phase 2	NA	[9]
DFD-29	DM478BI	Phase 2	NA	[9]
DMT210	DMK9PMK	Phase 2	Small molecular drug	[9]
IDP-115	DMGQS9N	Phase 2	NA	[13]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LAS-41001	DMXZ4BK	Discontinued in Preregistration	NA	[14]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DFD-09	DM450IZ	Application submitted	NA	[9]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SIG-990	DMC6LCF	Investigative	NA	[15]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
KLK5	TTULSEW	Limited	Biomarker	[16]
MRGPRX2	TT3YV20	Limited	Altered Expression	[17]
TRPV3	TT946IA	Limited	Genetic Variation	[18]
CAMP	TTULOB6	Strong	Altered Expression	[19]

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAMDEC1	OTMT7ZMG	Limited	Biomarker	[20]
DIO2	OTGPNSLH	Limited	Altered Expression	[21]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[22]
HLA-DRA	OT7KZMP2	Strong	Genetic Variation	[22]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Cortisone acetate FDA Label
• [3] Dexamethasone FDA Label
• [4] Dromostanolone FDA Label
• [5] Fluorometholone FDA Label
• [6] Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995 Jan;79(1):42-5.
• [7] Hydrocortisone FDA Label
• [8] Medrysone FDA Label
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Prednisolone FDA Label
• [11] Tobramycin FDA Label
• [12] ClinicalTrials.gov (NCT00940992) A Study of DER 45-EV Gel to Treat Rosacea. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT00667173) A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea. U.S. National Institutes of Health.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027956)
• [15] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [16] Cathelicidin, kallikrein 5, and serine protease activityis inhibited during treatment of rosacea with azelaic acid 15% gel.J Am Acad Dermatol. 2013 Oct;69(4):570-7. doi: 10.1016/j.jaad.2013.05.019. Epub 2013 Jul 18.
• [17] Emerging Roles for MAS-Related G Protein-Coupled Receptor-X2 in Host Defense Peptide, Opioid, and Neuropeptide-Mediated Inflammatory Reactions.Adv Immunol. 2017;136:123-162. doi: 10.1016/bs.ai.2017.06.002. Epub 2017 Jul 24.
• [18] Structure and gating mechanism of the transient receptor potential channel TRPV3.Nat Struct Mol Biol. 2018 Sep;25(9):805-813. doi: 10.1038/s41594-018-0108-7. Epub 2018 Aug 20.
• [19] Innate Immune Dysfunction in Rosacea Promotes Photosensitivity and Vascular Adhesion Molecule Expression.J Invest Dermatol. 2020 Mar;140(3):645-655.e6. doi: 10.1016/j.jid.2019.08.436. Epub 2019 Aug 29.
• [20] ADAMDEC1 promotes skin inflammation in rosacea via modulating the polarization of M1 macrophages.Biochem Biophys Res Commun. 2020 Jan 1;521(1):64-71. doi: 10.1016/j.bbrc.2019.10.073. Epub 2019 Oct 16.
• [21] Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes.Hum Mol Genet. 2018 Aug 1;27(15):2762-2772. doi: 10.1093/hmg/ddy184.
• [22] Genetic Predisposition to Rosacea.Dermatol Clin. 2018 Apr;36(2):87-92. doi: 10.1016/j.det.2017.11.002. Epub 2017 Dec 16.